Validation of a reinforcement learning policy for dosage optimization of erythropoietin

Authors:
José D. Martín-Guerrero;Emilio Soria-Olivas;Marcelino Martínez-Sober;Mónica Climente-Martí;Teresa De Diego-Santos;N. Víctor Jiménez-Torres
Affiliations:
Department of Electronic Engineering, University of Valencia, Spain;Department of Electronic Engineering, University of Valencia, Spain;Department of Electronic Engineering, University of Valencia, Spain;Pharmacy Unit, University Hospital Dr. Peset, Valencia, Spain;Pharmacy Unit, University Hospital Dr. Peset, Valencia, Spain;Pharmacy Unit, University Hospital Dr. Peset, Valencia, Spain and Department of Pharmacy and Pharmaceutical Technology, University of Valencia, Spain
Venue:
AI'07 Proceedings of the 20th Australian joint conference on Advances in artificial intelligence
Year:
2007

Citing 6
Cited 1

Drug delivery optimization through Bayesian networks: an application to erythropoietin therapy in uremic anemia

Computers and Biomedical Research - Papers presented at the 16th symposium on computer applications in medical care (SCAMC)
Neural Networks: A Comprehensive Foundation

Neural Networks: A Comprehensive Foundation
Introduction to Reinforcement Learning

Introduction to Reinforcement Learning
Neuro-Dynamic Programming

Neuro-Dynamic Programming
Pharmacodynamic population analysis in chronic renal failure using artificial neural networks: a comparative study

Neural Networks - 2003 Special issue: Advances in neural networks research — IJCNN'03
2005 Special Issue: Individualization of pharmacological anemia management using reinforcement learning

Neural Networks - 2005 Special issue: IJCNN 2005

Use of Reinforcement Learning in Two Real Applications

Recent Advances in Reinforcement Learning

Quantified Score

Hi-index	0.00

Visualization

Abstract

This paper deals with the validation of a Reinforcement Learning (RL) policy for dosage optimization of Erythropoietin (EPO). This policy was obtained using data from patients in a haemodialysis program during the year 2005. The goal of this policy was to maintain patients' Haemoglobin (Hb) level between 11.5 g/dl and 12.5 g/dl. An individual management was needed, as each patient usually presents a different response to the treatment. RL provides an attractive and satisfactory solution, showing that a policy based on RL would be much more successful in achieving the goal of maintaining patients within the desired target of Hb than the policy followed by the hospital so far. In this work, this policy is validated using a cohort of patients treated during 2006. Results show the robustness of the policy that is also successful with this new data set.